ALPINE IMMUNE SCIENCES, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 26 rows in 2015. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2015-09-11: Reporting owner Shoemaker Steven; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2015-09-11: Reporting owner Carruthers R Michael; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2015-09-11: Reporting owner LEFF JONATHAN S; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2015-09-11: Reporting owner Gabriel Sherif; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2015-09-11 | Shoemaker Steven Officer (VP Clinical R&D) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,700 39,700 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-09-11 | Carruthers R Michael Officer (Exec VP/CFO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +55,400 55,400 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-09-11 | LEFF JONATHAN S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,650 7,650 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-09-11 | Gabriel Sherif Officer (Vice President Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,700 24,700 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-09-11 | MOORE JOHN R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,650 7,650 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-09-11 | TROHA JANICE Officer (Exec. VP/COO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,400 65,400 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-09-11 | Furst Howard P. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,650 7,650 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-09-11 | Congleton Jon Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +121,100 121,100 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-09-11 | Loh Evan Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,650 7,650 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-09-11 | CONWAY ROBERT E Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,650 7,650 owned after | $15.28 exercise price | 2015-09-15 | |
| 2015-07-16 | LEFF JONATHAN S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,475 11,475 owned after | $17.49 exercise price | 2015-07-20 | |
| 2015-07-16 | Furst Howard P. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,475 11,475 owned after | $17.49 exercise price | 2015-07-20 | |
| 2015-07-16 | CONWAY ROBERT E Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,475 11,475 owned after | $17.49 exercise price | 2015-07-20 | |
| 2015-06-16 holding as of filing | Congleton Jon Director, Officer (President & CEO) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.57 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | TROHA JANICE Officer (Executive VP & COO) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $3.36 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | TROHA JANICE Officer (Executive VP & COO) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.57 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | Loh Evan Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $3.36 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | Loh Evan Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.57 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | MOORE JOHN R Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $3.36 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | MOORE JOHN R Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.57 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | Carruthers R Michael Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.57 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | Gabriel Sherif Officer (VP of Research & Discovery) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $3.36 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | Gabriel Sherif Officer (VP of Research & Discovery) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.57 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | Gabriel Sherif Officer (VP of Research & Discovery) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.57 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | Shoemaker Steven Officer (VP of Clinical R & D & Med Dir) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $3.36 exercise price | 2015-06-16 | ||
| 2015-06-16 holding as of filing | Shoemaker Steven Officer (VP of Clinical R & D & Med Dir) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.57 exercise price | 2015-06-16 |